D-PENAMINE 125 mg Oral Tablet
RxNorm 2103018
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2103018 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: D-PENAMINE 125 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
PSN
Prescribable Name (PSN):
D-PENAMINE 125 mg Oral Tablet
(Atom ID: 10776710)
SY
Synonym (SY):
D-Penamine 125 mg Oral Tablet
(Atom ID: 10776711)
SBD
Semantic Branded Drug (SBD):
Penicillamine 125 mg Oral Tablet [D-Penamine]
(Atom ID: 12372079)
TMSY
Tall Man Lettering Synonym (TMSY):
PenicillAMINE 125 mg Oral Tablet [D-Penamine]
(Atom ID: 12430563)
Patient Education
Penicillamine
Penicillamine is used to treat Wilson's disease (an inherited condition that causes copper to build up in the body and may result in serious symptoms) and cystinuria (an inherited condition which can lead to kidney stones). It is also used in combination with other treatments to treat severe rheumatoid arthritis (a condition in which the body's immune system attacks its own joints, causing pain, swelling, and loss of function) that did not get better after treatment with other medications. Penicillamine is in a class of medications called heavy metal antagonists. It works to treat Wilson's disease by binding to the extra copper in the body and causing it to leave the body through the urine. It works to treat cystinuria by binding to the substance that makes kidney stones and preventing it from building up and forming stones. It works to treat rheumatoid arthritis by decreasing some actions of the immune system.
[Learn More]
* Please review the disclaimer below.